people

Peter Beetham (left) has been named president and CEO of gene the board of direc- editing company Cibus (San Diego), following the retirement of tors. Murray brings Keith Walker, who had led the company since its founding in 2001. more than 20 years Beetham was previously senior vice president of R&D. Current vice of experience in the president of research Greg Gocal has been promoted to succeed biotech and pharma Beetham, and Walker has been named to Cibus’ board of directors. industries, serving “Peter’s intimate work as a member of the original founding most recently as group, his knowledge from leading the development efforts for the senior vice presi- Cibus’ core technology coupled with his management of Cibus’ R&D dent, biologics and efforts make him the ideal candidate to lead Cibus in its next stage of commercialization research at Merck. He was also a and growth of its technology across the global market,” said Rory Riggs, chairman of the member of the Merck Research Laboratories board of Cibus. leadership team.

Illumina (San Diego) has announced that Tris Pharma (Monmouth Junction, NJ, . Gutterson joins the company Tina S. Nova has been appointed senior vice USA) has announced the additions of Sally from Mendel Biotechnology, where he was president and general manager of its oncol- A. Berry and Norma Cappetti to its man- president, CEO and a member of the board. ogy business. Rick Klausner, who had served agement team. Berry joins Tris as chief He is currently on the board of trustees for as interim oncology leader since January medical officer. She was most recently with the wheat and maize agricultural nonprofit 2014, will continue in his role as Illumina’s and previously served as chief medi- CIMMYT and has served eight years on the senior vice president and chief medical offi- cal officer of NextWave Pharmaceuticals. food and agriculture section governing board cer. Nova previously co-founded Genoptix Cappetti will serve as vice president of reg- of the Biotechnology Industry Organization. and served as its president and CEO. She was ulatory affairs. She joins Tris with over 25 a member of the Genoptix board of directors years of experience in managing and leading Life sciences investment group Abingworth until it was acquired by Novartis in 2011. regulatory affairs in the pharma industry at (London) has announced the promotions of Ono Pharma, Celltech Americas, Medeva Ken Haas and Vin Miles to partner. Haas Robert G. Pietrusko Americas and Fisons. has 25 years of experience in both early-stage (left) has joined gene and public high technology and biotech com- therapy company America, Inc. All rights reserved. America, Inc. © 201 4 Nature Forum Pharmaceuticals (Watertown, MA, pany management. He joined Abingworth in Voyager Therapeutics USA) has named Christine Boisclair vice 2004. Miles has more than 30 years of man- (Cambridge, MA, president, regulatory affairs. She most agement experience in the biotech indus- USA) as senior vice npg recently served in the same capacity at try, and currently serves on the boards of president of regula- Insmed Inc. and as senior vice president, Chiasma, Dicerna, Hydra BioSciences and tory affairs. He brings global regulatory affairs at Agennix. Magellan Bioscience. He joined Abingworth to the company more in 2007. Both Haas and Miles will be based than three decades of experience in regulatory Akebia Therapeutics (Cambridge, MA, USA) in the US. affairs and pharmaceutical drug development. has named Michael D. Clayman and Maxine Previously, he was vice president, global regula- Gowen to its board of directors. In addition, Therapeutics (Cambridge, MA, tory affairs and quality and executive officer at Kim L. Dueholm has stepped down from the USA) has named Stephen Kelsey as presi- ViroPharma, until the company’s acquisition board. Clayman is a co-founder of Flexion dent of Onkaido Therapeutics, Moderna’s by Shire in January. Therapeutics and serves as president and CEO. newly launched oncology drug development Gowen is president and CEO of Trevena. company. Kelsey previously served as Geron’s Raptor Pharmaceuticals (Novato, CA, USA) executive vice president of R&D and chief has announced the promotion of executive Agena Bioscience (San Diego) has named medical officer, and was most recently senior vice president, strategy and COO Julie Anne Peter Dansky CEO and a member of the vice president, new projects at the cancer Smith to president and CEO-designate. She board of directors. Dansky was formerly therapies company Medivation. will succeed Christopher Starr as CEO and president of the molecular and cell biology will join the board effective January 1, 2015. division of Life Technologies. Richard Murray (below) has been named Starr will continue working closely with Smith CEO of Jounce Therapeutics (Cambridge, during the transition period, will remain on DuPont Pioneer (Des Moines, IA, USA) MA, USA), succeeding interim CEO Cary the board of directors and will consult on has announced the appointment of Neal Pfeffer, a partner at Third Rock Ventures Raptor development projects following the Gutterson as vice president of agricultural who will assume the position of chairman of succession.

844 volume 32 NUMBER 8 AUGUST 2014 nature biotechnology